# 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

> **NCT02605304** · PHASE2 · TERMINATED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 7 (actual)

## Conditions studied

- HIV-1 Infection
- Hepatitis C

## Interventions

- **DRUG:** Ledipasvir/sofosbuvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02605304
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-17
- **Primary completion:** 2017-01-20
- **Final completion:** 2017-03-20
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The study experienced enrollment difficulties.
- **Last updated:** 2018-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605304, "12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02605304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*